Treatment of egf-receptor dependent pathologies

A method for treating a subject with an EGFR dependent pathology, comprising the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2.

5-7. (canceled)

11-13. (canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

A method of identifying an agent which can be used in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1) for the treatment of an EGFR dependent pathology, comprising the steps of

• a) combining TACE, iRhom 1 (or iRhom2) and a test agent under conditions suitable for forming a complex between TACE and iRhom1 (or iRhom2);
• and
• b) assessing the quantity of complex formation between TACE and iRhom1 (or iRhom2), wherein diminished or increased complex formation between TACE and iRhom1 (or iRhom2) in the presence of the test agent than in the absence is indicative that the test agent is useful for the treatment of an EGFR dependent pathology in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1).

A method of identifying an agent which can be used in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1) for the treatment of an EGFR dependent pathology, comprising the steps of

• a) combining a test agent and a cell which releases an EGFR ligand under conditions suitable for stimulating release of the EGFR ligand, wherein the cell is iRhom2−/− (or iRhom1−/−) or wherein an inhibitor of a biological activity of iRhom2 (or iRhom1) is additionally combined with the cell and test agent;
• and
• b) assessing the quantity of released EGFR ligand, wherein diminished EGFR ligand release in the presence of the test agent than in the absence is indicative that the test agent is useful in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1) for the treatment of an EGFR dependent pathology.

31-33. (canceled)

A method of identifying an agent which can be used in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1) for the treatment of an EGFR dependent pathology, comprising the following steps:

• a) combining a test agent and a cell which expresses the mature 100 kD form of TACE under conditions suitable for expression of the mature 100 kD form of TACE, and wherein the cell is either iRhom2−/− (or iRhom1−/−) or an inhibitor of iRhom2 (or iRhom1) is additionally combined with the cell and test agent;
• and
• b) assessing the quantity of the mature 100 kD form of TACE that is formed, wherein diminished formation of the mature 100 kD form of TACE in the presence of the test agent than in the absence is indicative that the test agent is useful in combination with an inhibitor of a biological activity of iRhom2 (or iRhom1) for the treatment of an EGFR dependent pathology.